NASDAQ:VXRTVaxart Stock Price, Forecast & News

Vaxart's stock was trading at $2.07 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, VXRT stock has increased by 339.6% and is now trading at $9.10.
View which stocks have been most impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vaxart in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Vaxart.

Vaxart is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020.
View our earnings forecast for Vaxart.

Vaxart Inc (NASDAQ:VXRT) released its quarterly earnings data on Thursday, August, 6th. The biotechnology company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.06) by $0.06. Vaxart had a negative return on equity of 94.20% and a negative net margin of 252.86%.
View Vaxart's earnings history.

Vaxart shares reverse split on Wednesday, February 14th 2018. The 1-11 reverse split was announced on Tuesday, February 13th 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 13th 2018. An investor that had 100 shares of Vaxart stock prior to the reverse split would have 9 shares after the split.

3 brokerages have issued 1 year price objectives for Vaxart's shares. Their forecasts range from $6.00 to $22.00. On average, they expect Vaxart's stock price to reach $11.67 in the next year. This suggests a possible upside of 28.2% from the stock's current price.
View analysts' price targets for Vaxart.

Headlines about VXRT stock have been trending positive on Friday, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Vaxart earned a media sentiment score of 2.1 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days.
View the latest news about Vaxart.

Some companies that are related to Vaxart include Halozyme Therapeutics (HALO), Iovance Biotherapeutics (IOVA), Momenta Pharmaceuticals (MNTA), Ablynx (ABLYF), bluebird bio (BLUE), Sorrento Therapeutics (SRNE), Twist Bioscience (TWST), Fate Therapeutics (FATE), Denali Therapeutics (DNLI), Immunovant (IMVT), SpringWorks Therapeutics (SWTX), Mesoblast (MESO), Editas Medicine (EDIT), Legend Biotech (PCVX) and Sangamo Therapeutics (SGMO).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Vaxart investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Novavax (NVAX), VBI Vaccines (VBIV), Conatus Pharmaceuticals (CNAT), Crispr Therapeutics (CRSP), Advanced Micro Devices (AMD), Johnson & Johnson (JNJ), Agile Therapeutics (AGRX) and Co-Diagnostics (CODX).

Vaxart trades on the NASDAQ under the ticker symbol "VXRT."

Vaxart's stock is owned by a variety of institutional and retail investors. Top institutional investors include UBS Group AG (0.28%), Hussman Strategic Advisors Inc. (0.18%), Russell Investments Group Ltd. (0.04%), National Asset Management Inc. (0.04%), Cambridge Investment Research Advisors Inc. (0.03%) and Strategic Wealth Management Group LLC (0.04%). Company insiders that own Vaxart stock include Armistice Capital Master Fund, Armistice Capital, Llc, John P Richard, Michael J Finney, Sean Tucker, Todd C Davis and Wouter Latour.
View institutional ownership trends for Vaxart.

VXRT stock was sold by a variety of institutional investors in the last quarter, including Hussman Strategic Advisors Inc.. Company insiders that have sold Vaxart company stock in the last year include Armistice Capital, Llc, and Todd C Davis.
View insider buying and selling activity for Vaxart.

VXRT stock was acquired by a variety of institutional investors in the last quarter, including UBS Group AG, Russell Investments Group Ltd., National Asset Management Inc., Cambridge Investment Research Advisors Inc., SG Americas Securities LLC, Strategic Wealth Management Group LLC, Strs Ohio, and Ameritas Investment Partners Inc.. Company insiders that have bought Vaxart stock in the last two years include Armistice Capital Master Fund, John P Richard, Michael J Finney, Sean Tucker, and Wouter Latour.
View insider buying and selling activity for Vaxart.

Shares of VXRT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of VXRT stock can currently be purchased for approximately $9.10.

Vaxart has a market capitalization of $992.72 million and generates $9.86 million in revenue each year. The biotechnology company earns $-18,650,000.00 in net income (profit) each year or ($0.86) on an earnings per share basis. Vaxart employs 34 workers across the globe.

The official website for Vaxart is www.vaxart.com.

Vaxart's mailing address is 290 Utah Ave. Suite 200, South San Francisco CA, 94080. The biotechnology company can be reached via phone at 650-550-3500 or via email at [email protected]